4-methylpiperazine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester | 705966-33-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-methylpiperazine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester
• 英文别名: 2-methyl 1-(phenylmethyl) 4-methyl-1,2-piperazinedicarboxylate；1-Benzyl 2-methyl 4-methylpiperazine-1,2-dicarboxylate；1-O-benzyl 2-O-methyl 4-methylpiperazine-1,2-dicarboxylate
• CAS: 705966-33-2
• 化学式: C₁₅H₂₀N₂O₄
• 分子量: 292.335
• InChiKey: KTQSBVBTZIRSGQ-UHFFFAOYSA-N

物化性质

• 沸点：
  398.1±42.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-methylpiperazine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以96%的产率得到methyl 4-methylpiperazine-2-carboxylate hydrochloride
  参考文献：
  名称：

  Synthesis, resolution, and absolute configuration of novel tricyclic benzodiazepines

  摘要：

  The synthesis, resolution, and stereochemical characterization of novel piperazino-, thiazino-, and oxazinoberizodiazepines are described. The absolute stereochemistry of the heterotricycles was determined by using X-ray crystallography and the enantiomeric purity was determined by using Pirkle-solvent NMR techniques and chiral HPLC. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2004.02.028
• 作为产物：
  描述：

  (+/-)-1-苄氧羰基-4-Boc-哌嗪-2-羧酸甲酯 在 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 6.0h， 生成 4-methylpiperazine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester
  参考文献：
  名称：

  Synthesis, resolution, and absolute configuration of novel tricyclic benzodiazepines

  摘要：

  The synthesis, resolution, and stereochemical characterization of novel piperazino-, thiazino-, and oxazinoberizodiazepines are described. The absolute stereochemistry of the heterotricycles was determined by using X-ray crystallography and the enantiomeric purity was determined by using Pirkle-solvent NMR techniques and chiral HPLC. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2004.02.028

文献信息

• New and versatile approaches to the synthesis of CPP-related competitive NMDA antagonists. Preliminary structure activity relationships and pharmacological evaluation
  作者：Sheryl J. Hays、Christopher F. Bigge、Perry M. Novak、James T. Drummond、Thomas P. Bobovski、Michael J. Rice、Graham Johnson、Laura J. Brahce、Linda L. Coughenour

  DOI：10.1021/jm00172a037

  日期：1990.10

  Fourteen new CPP analogues have been prepared with methyl 1-(phenylmethyl) (+/-)-1,2-piperazinedicarboxylate 3 as a versatile synthetic intermediate. Derivatives were evaluated as NMDA ligands by their ability to displace [3H]CPP from rat cortical membranes. The binding affinity of various chain lengths at the N4-position of the CPP analogues, 5a, 5b, and 9a mimics the binding affinity observed for

  已经用1-（苯基甲基）（+/-）-1,2-哌嗪二羧酸甲酯3作为通用的合成中间体制备了十四种新的CPP类似物。通过从大鼠皮膜置换[3H] CPP的能力，将衍生物评估为NMDA配体。在CPP类似物5a，5b和9a的N4位的各种链长的结合亲和力模拟了对无环衍生物AP6，AP8和AP5观察到的结合亲和力。与结构相似的哌啶化合物CGS 19755相比，在其膦酸酯侧链中具有一个亚甲基的类似物9a对NMDA受体的亲和力降低。用可单电离的酸性基团（例如羧酸根或次膦酸根）取代膦酸部分降低结合亲和力。N4-氮和远端酸性基团之间的芳基间隔基对键合有害，就像在N1-位上的烷基化一样。然而，如类似物21和22所示，当苯基位于膦酸酯的α处时，对立体异构体的耐受性更好。
• [EN] USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT ALLERGIC RHINITIS<br/>[FR] METHODE DE TRAITEMENT DE RHINITE ALLERGIQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004022061A1

  公开（公告）日：2004-03-18

  A method to treat allergic rhinitis is disclosed in which patients are administered certain indolyl compounds.

  揭示了一种治疗过敏性鼻炎的方法，其中患者被施用特定的吲哚化合物。
• Heterocyclic compounds
  申请人：——

  公开号：US20030207893A1

  公开（公告）日：2003-11-06

  Heterocyclic compounds and methods of making them and using them.

  杂环化合物及其制备和使用方法。
• Method to treat allergic rhinitis
  申请人：——

  公开号：US20040132715A1

  公开（公告）日：2004-07-08

  A method to treat allergic rhinitis is disclosed in which patients are administered certain indolyl compounds.

  本发明揭示了一种治疗过敏性鼻炎的方法，其中患者被给予某些吲哚类化合物。
• HETEROCYCLIC COMPOUNDS
  申请人：Janssen Pharmaceuticals, Inc.

  公开号：EP1373204B1

  公开（公告）日：2016-10-26